Trends and disparities in hospice care utilization in testicular cancer in the United States of America from 2003 to 2020: Analysis of CDC WONDER database.

Wonder Hospice care
DOI: 10.1200/jco.2024.42.4_suppl.504 Publication Date: 2024-01-29T21:06:41Z
ABSTRACT
504 Background: Testicular cancer (TC) is a malignancy with five-year survival reaching up to 95%. It estimated that 470 deaths from this disease will occur in the United States 2023. Even exceptional rates, it important recognize need of hospice these patients. Enrollment associated lower healthcare costs, symptom burden, and psychological distress improved quality life. We used publicly available CDC WONDER (Centers for Disease Control Prevention Wide-ranging Online Data Epidemiologic Research) database aim explore trends utilization patients testicular nationwide US. Methods: The search analysis were conducted using January 01, 2003, December 31, 2020. data due TC pooled International Classification Diseases-10th Revision codes C62, C62.0, C62.1 C62.9. inclusion criteria included males aged >15 years. demographic was obtained calculate descriptive statistics age, census region, mortality accordingly over past two decades. Results: demonstrated overall 6,969 2003-2020. Of deaths, 520 (7.46%) recorded facilities. According US regions, highest number Census Region 3: South (CENS-R3) 8.99%, followed by 1: Northeast (CENS-R1) 8.03%, 2: Midwest (CENS-R2) 7.23%. While lowest observed 4: West (CENS-R4) at 5.30%. 1.9% 2005 increased years 10.4% 2019, slight decline 2020 which 7.9%. Moreover, when stratified age groups, mortalities are group 15-34 (6.32%), 35-54 (7.08%), 55-74 (10.10%), 75-85+ (8.72%). Conclusions: To our knowledge first study utilizing demonstrate care related deaths. steady increase 2005-2019 throughout possibly COVID pandemic. Age stratification further revealed compared highlighting improve discussions early group. This highlights disparities end-of-life should promote policy-level changes states services access
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)